Two interesting things about the OncoBEAM RAS CRC technology are that it can give more accurate results for plasma KRAS mutation assaying in patients with mCRC than the Idylla system [67] and that it can do a wider range of quantitative tests [95]. The gene discussed is KRAS; the disease is colorectal carcinoma.